Charles Schwab Investment Management Inc Regenxbio Inc. Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Regenxbio Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 417,739 shares of RGNX stock, worth $3.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
417,739
Previous 380,684 9.73%
Holding current value
$3.37 Million
Previous $4.45 Million 1.62%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$10.49 - $14.39 $388,706 - $533,221
37,055 Added 9.73%
417,739 $4.38 Million
Q2 2024

Aug 12, 2024
BUY
$11.51 - $21.53 $426,664 - $798,095
37,069 Added 10.79%
380,684 $4.45 Million
Q1 2024

May 08, 2024
BUY
$12.17 - $24.61 $196,715 - $397,796
16,164 Added 4.94%
343,615 $7.24 Million
Q4 2023

Feb 06, 2024
BUY
$12.89 - $20.82 $21,693 - $35,040
1,683 Added 0.52%
327,451 $5.88 Million
Q3 2023

Nov 08, 2023
BUY
$16.46 - $19.99 $454,131 - $551,524
27,590 Added 9.25%
325,768 $5.36 Million
Q2 2023

Aug 09, 2023
BUY
$17.23 - $21.71 $147,678 - $186,076
8,571 Added 2.96%
298,178 $5.96 Million
Q1 2023

May 11, 2023
BUY
$18.08 - $24.55 $36,883 - $50,082
2,040 Added 0.71%
289,607 $5.48 Million
Q4 2022

Feb 13, 2023
BUY
$20.4 - $24.73 $178,275 - $216,115
8,739 Added 3.13%
287,567 $6.52 Million
Q3 2022

Nov 14, 2022
BUY
$22.29 - $35.04 $98,766 - $155,262
4,431 Added 1.61%
278,828 $7.37 Million
Q2 2022

Aug 15, 2022
SELL
$19.35 - $35.04 $249,402 - $451,630
-12,889 Reduced 4.49%
274,397 $6.78 Million
Q1 2022

May 13, 2022
SELL
$24.62 - $34.31 $23,438 - $32,663
-952 Reduced 0.33%
287,286 $9.54 Million
Q4 2021

Feb 11, 2022
BUY
$30.19 - $40.28 $106,812 - $142,510
3,538 Added 1.24%
288,238 $9.43 Million
Q3 2021

Nov 16, 2021
BUY
$29.09 - $45.68 $566,411 - $889,435
19,471 Added 7.34%
284,700 $11.9 Million
Q2 2021

Aug 16, 2021
BUY
$32.46 - $40.48 $629,951 - $785,595
19,407 Added 7.89%
265,229 $10.3 Million
Q1 2021

May 17, 2021
BUY
$33.61 - $49.95 $1.32 Million - $1.96 Million
39,328 Added 19.05%
245,822 $8.39 Million
Q4 2020

Feb 16, 2021
BUY
$26.52 - $49.35 $69,615 - $129,543
2,625 Added 1.29%
206,494 $9.37 Million
Q3 2020

Nov 13, 2020
SELL
$27.01 - $40.26 $322,715 - $481,026
-11,948 Reduced 5.54%
203,869 $5.61 Million
Q2 2020

Aug 14, 2020
BUY
$27.75 - $43.44 $356,781 - $558,508
12,857 Added 6.33%
215,817 $7.95 Million
Q1 2020

May 15, 2020
BUY
$21.5 - $54.2 $124,356 - $313,492
5,784 Added 2.93%
202,960 $6.57 Million
Q4 2019

Feb 07, 2020
BUY
$34.54 - $44.87 $154,842 - $201,152
4,483 Added 2.33%
197,176 $8.08 Million
Q3 2019

Nov 08, 2019
BUY
$31.84 - $50.88 $218,708 - $349,494
6,869 Added 3.7%
192,693 $6.86 Million
Q2 2019

Aug 09, 2019
SELL
$42.0 - $59.29 $982,128 - $1.39 Million
-23,384 Reduced 11.18%
185,824 $9.55 Million
Q1 2019

May 14, 2019
BUY
$40.82 - $62.45 $661,243 - $1.01 Million
16,199 Added 8.39%
209,208 $12 Million
Q4 2018

Feb 14, 2019
BUY
$39.11 - $75.15 $253,980 - $488,024
6,494 Added 3.48%
193,009 $8.1 Million
Q3 2018

Nov 13, 2018
BUY
$65.0 - $82.15 $2.75 Million - $3.48 Million
42,307 Added 29.34%
186,515 $14.1 Million
Q2 2018

Aug 08, 2018
BUY
$27.2 - $74.35 $247,900 - $677,625
9,114 Added 6.75%
144,208 $10.3 Million
Q1 2018

May 07, 2018
BUY
$24.05 - $37.5 $166,113 - $259,012
6,907 Added 5.39%
135,094 $4.03 Million
Q4 2017

Jan 17, 2018
BUY
$26.0 - $34.6 $147,628 - $196,458
5,678 Added 4.63%
128,187 $4.26 Million
Q3 2017

Nov 13, 2017
BUY
$18.0 - $32.95 $2.21 Million - $4.04 Million
122,509
122,509 $4.04 Million

Others Institutions Holding RGNX

# of Institutions
186
Shares Held
43.1M
Call Options Held
104K
Put Options Held
478K
View Full List

About REGENXBIO Inc.

RGNX Quotes by TradingView
  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $349M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email